These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 9280681)
1. [PET and SPECT in Parkinson's disease]. Blesa R Rev Neurol; 1997 Aug; 25 Suppl 2():S147-50. PubMed ID: 9280681 [TBL] [Abstract][Full Text] [Related]
2. [SPECT and PET in Parkinson's disease]. Matsuda H Nihon Rinsho; 2000 Oct; 58(10):2000-6. PubMed ID: 11068438 [TBL] [Abstract][Full Text] [Related]
3. PET and SPECT functional imaging in Parkinson's disease. Antonini A; DeNotaris R Sleep Med; 2004 Mar; 5(2):201-6. PubMed ID: 15033144 [TBL] [Abstract][Full Text] [Related]
4. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Thobois S; Guillouet S; Broussolle E Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273 [TBL] [Abstract][Full Text] [Related]
5. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497 [TBL] [Abstract][Full Text] [Related]
6. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182 [TBL] [Abstract][Full Text] [Related]
7. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. Brücke T; Djamshidian S; Bencsits G; Pirker W; Asenbaum S; Podreka I J Neurol; 2000 Sep; 247 Suppl 4():IV/2-7. PubMed ID: 11199811 [TBL] [Abstract][Full Text] [Related]
8. [Neurotransmitter systems in the human brain studied by positron emission tomography]. Shinotoh H Rinsho Shinkeigaku; 1996 Dec; 36(12):1313-5. PubMed ID: 9128390 [TBL] [Abstract][Full Text] [Related]
9. Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Fernandez HH; Friedman JH; Fischman AJ; Noto RB; Lannon MC Med Sci Monit; 2001; 7(6):1339-43. PubMed ID: 11687754 [TBL] [Abstract][Full Text] [Related]
11. Neuroimaging in Parkinson's disease: from pathology to diagnosis. Stoessl AJ Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S55-9. PubMed ID: 22166455 [TBL] [Abstract][Full Text] [Related]
12. PET and SPECT studies in Parkinson's disease. Brooks DJ Baillieres Clin Neurol; 1997 Apr; 6(1):69-87. PubMed ID: 9426869 [TBL] [Abstract][Full Text] [Related]
13. The use of PET in Parkinson's disease. Shinotoh H; Calne DB Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856 [TBL] [Abstract][Full Text] [Related]
14. [Neurotransmitter-receptor-imaging]. Cordes M; Hierholzer J; Nikolai-Beyer K Radiologe; 1993 Nov; 33(11):612-9. PubMed ID: 7904078 [TBL] [Abstract][Full Text] [Related]
15. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. Ceballos-Baumann AO J Neurol; 2003 Feb; 250 Suppl 1():I15-23. PubMed ID: 12761630 [TBL] [Abstract][Full Text] [Related]
16. [Value of functional imaging in Parkinson's disease and related movement disorders]. Heiss WD; Würker M Nervenarzt; 1999 Jan; 70 Suppl 1():S2-10. PubMed ID: 10087524 [TBL] [Abstract][Full Text] [Related]
17. Functional imaging in Parkinson's disease. Dagher A Semin Neurol; 2001; 21(1):23-32. PubMed ID: 11346022 [TBL] [Abstract][Full Text] [Related]
18. [Molecular imaging in Parkinson's disease]. Arahata Y; Kato T; Ito K Nihon Rinsho; 2007 Feb; 65(2):327-31. PubMed ID: 17302279 [TBL] [Abstract][Full Text] [Related]
19. Molecular imaging of movement disorders. Lizarraga KJ; Gorgulho A; Chen W; De Salles AA World J Radiol; 2016 Mar; 8(3):226-39. PubMed ID: 27029029 [TBL] [Abstract][Full Text] [Related]